文献速递皮肤肿瘤

阿司匹林与非甾体抗炎药使用与角质形成细胞癌:澳大利亚大型人群队列研究

Aspirin and nonsteroidal anti-inflammatory drug use and keratinocyte cancers: a large population-based cohort study of skin cancer in Australia.
PubMed 文献 · Br J Dermatol · 2019-05-02

BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) have been postulated as chemopreventive agents for basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), but findings from observational studies have been inconsistent, and clinical trial data are scant.…

要点

  • 平均至低风险人群中未观察到NSAID或阿司匹林与BCC/SCC的关联。

核心结论

  • 观察到的阿司匹林或NSAID与皮肤癌的弱负相关模式不一致,不能提供令人信服的证据表明这些药物降低后续皮肤癌风险。

研究设计与样本

  • 使用Cox比例风险模型估计风险比(HR),暴露为基线前1年自我报告的阿司匹林和NSAID使用。
  • 结局为首次组织学确诊的BCC或SCC,按高风险和平均至低风险分层分析。

主要发现

  • 中位随访3年,3421人发生BCC,1470人发生SCC(2288例BCC和932例SCC有完整协变量信息)。
  • 平均至低风险人群中,NSAID或阿司匹林使用与BCC或SCC风险均无关联。

关键数值与推荐

  • 高风险定义:有皮肤癌切除史或治疗超过5个光化性病变。
  • 平均至低风险定义:无皮肤癌切除史且治疗最多5个光化性病变。
  • 频繁NSAID使用定义为至少每周一次;不频繁阿司匹林使用定义为少于每周一次。

临床怎么用

  • 目前证据不足以推荐阿司匹林或NSAID用于皮肤癌化学预防。
  • 在高风险人群中观察到的弱关联需进一步研究剂量、 duration和长期随访以理解累积剂量效应。

局限性

  • 观察性设计不能排除混杂和反向因果关系。
  • 暴露为自我报告,可能存在错分。
  • 部分分析样本因协变量信息缺失而减少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) have been postulated as chemopreventive agents for basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), but findings from observational studies have been inconsistent, and clinical trial data are scant. OBJECTIVES: To examine the association between aspirin and NSAID (nonaspirin) use and the risk of BCC and SCC in a large cohort specifically designed for skin cancer outcomes. METHODS: We used data from the QSkin Study, a prospective cohort of 43 764 residents of Queensland, Australia (34 630 were included in this study and 23 581 were used in our primary analyses). We used Cox proportional hazards models to estimate the hazard ratios (HRs) between self-reported aspirin and NSAID use 1 year prior to study baseline and the first histologically confirmed BCC or SCC for high-risk (history of skin cancer excisions or more than five actinic lesions treated) and average-to-low-risk participants (no history of skin cancer excision and at most five actinic lesions treated). RESULTS: After a median of 3 years of follow-up, 3421 participants developed BCC and 1470 SCC (2288 BCC and 932 SCC with complete covariate information). Among the high-risk group (1826 BCC and 796 SCC), compared with never use, frequent (at least weekly) NSAID use was associated with reduced risk of BCC (HR 0·84, 95% confidence interval 0·71-0.99) but not SCC. Aspirin use was associated with reduced risk of SCC (HR 0·77, 95% confidence interval 0·64-0·93) only among infrequent (less than weekly) users and was not associated with BCC. We observed no association between NSAID or aspirin use and the risk of BCC or SCC among average-to-low-risk participants. CONCLUSIONS: While some weakly inverse associations were observed between prior use of aspirin or NSAIDs and skin cancer, the inconsistent patterns of associations do not provide convincing evidence that these medications reduce subsequent skin cancer risk. Further data on doses, duration and long-term follow-up may help us to comprehend the cumulative dose effect.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Pandeya N, Olsen CM, Thompson BS, et al. Aspirin and nonsteroidal anti-inflammatory drug use and keratinocyte cancers: a large population-based cohort study of skin cancer in Australia. Br J Dermatol. 2019. PMID: 30920641. doi:10.1111/bjd.17938

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。